Dextroamphetamine Sulfate
NDC Package 58177-312-04

11-digit billing NDC: 58177031204

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Dextroamphetamine Sulfate is tablets are indicated in: Narcolepsy. Marketed by Ethex Corporation, this product is identified by NDC 58177-312 and is authorized under FDA application ANDA040367.

Identification & Billing

NDC Package Code
58177-312-04
Package Description
100 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
58177031204
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Dextroamphetamine Sulfate
Dosage Form
-
Usage Information
Dextroamphetamine sulfate tablets are indicated in: Narcolepsy. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional liability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Regulatory & Marketing

Labeler Name
Ethex Corporation
FDA Application #
ANDA040367
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-01-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (58177-312). Click a package code to view its specific billing and regulatory data.

1000 TABLET in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58177-312-04 identifies a specific commercial package of 100 tablet in 1 bottle of Dextroamphetamine Sulfate, labeled by Ethex Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Ethex Corporation on November 01, 2009. The current certification is valid through December 31, 2017.

How is this Ethex Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58177031204. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
58177-312-04
11-Digit CMS (5-4-2)
58177-0312-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.